Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Dow, Cambrex Complete Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Dow, Cambrex Complete Facility

Partners launch site for Affinisol for solubility enhancement

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

The Dow Chemical Company and Cambrex have completed and opened the operational facility for Dow’s Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS) for Drug Solubility Enhancement. The facility is an expansion of   Cambrex’s Karlskoga site, and work began in early 2013.

The facility completion and start of HPMCAS product validation marks a year-long process that began with a solubilization partnership between Dow and Bend Research, announced in October 2012. Starting early 2014, Dow will be able to commercially supply solubility enabling excipients.

“We are proud to have completed this carefully executed expansion in such a short amount of time,” said Bjarne Sandberg, managing director of Cambrex Karlskoga. “This has been a great collaboration with both the Dow and Cambrex teams focused on meeting project goals. This partnership between Dow and Cambrex further demonstrates Cambrex’s commitment to finding solutions that allow our clients to meet a market need in a timely manner.”

“We are enthusiastic about commercially bringing the first solution of our Affinisol portfolio to the market,” said Marc van Gerwen, business director for Dow Pharma & Food Solutions. “Working with Cambrex, we were able promptly address the pharmaceutical industry’s most pressing need: advancing poorly soluble APIs to become therapeutically beneficial oral drug products.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics